JIANGXI BIOLOGY(06915.HK): Stabilisation Period Concludes, Over-Allotment Option Lapses
NewTimeSpace News: On 26 July 2026, JIANGXI BIOLOGY(06915.HK) issued an announcement stating that the stabilisation period in connection with its global offering concluded on 25 July 2026. During the stabilisation period, the stabilising manager over-allotted a total of 5,435,000 H-shares under the international offering, and repurchased a total of 5,435,000 H-shares on the market at prices ranging from HK$7.40 to HK$10.46 per share for delivery to placees who agreed to deferred settlement.
As the over-allotment option remained unexercised, it lapsed on 25 July 2026, and the Company did not issue any H-shares pursuant to the over-allotment option.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- JIANGXI BIOLOGY(06915.HK): Veterinary Tetanus Antitoxin Production Line Officially Put into Operation
- Jiangxi Biotech (06915.HK)Slumps 14.29% on Listing Day, Quoted at HK$9.60
- JIANGXI BIOLOGY(06915.HK) Launches Public Offering Today, Entry Fee Approximately HK$6,595.86
- Jiangxi Biology Passes HKEX Hearing, World’s Largest Provider of Human Tetanus Antitoxin
- JIANGXI BIO(06915.HK) closed 24.49% higher on Jul 24, eading the gains in the Hang Seng Pharmaceuticals & Biotechnology Sector